Voronoi KRX:310210KOSDAQ
보로노이 · Korean news coverage and regulatory filings, organized.
Articles, 24h3
Articles, 7 days6
DART filings, 7 days5
Articles tracked6since Sep 11
In Q2 2026, Voronoi reported revenue of ₩0m, down 100.0% year on year, and an operating loss of ₩29.3bn. Voronoi (보로노이) appeared in 6 Korean news articles and 5 DART filings over the past seven days. Coverage peaked on Sep 14 with 5 articles. The most common catalyst was clinical & approvals (1). It was most often mentioned alongside ImmuneOncia Therapeutics.
Voronoi quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩0m | -100.0% | −₩29.3bn | −₩29.0bn |
| Q1 2026 | ₩0m | – | −₩22.0bn | −₩22.0bn |
| Q4 2025 derived | ₩22m | – | −₩16.2bn | −₩4.3bn |
| Q3 2025 | ₩4.1bn | – | −₩13.6bn | −₩13.8bn |
| Q2 2025 | ₩3.4bn | – | −₩10.2bn | −₩10.5bn |
| Q1 2025 | ₩0m | – | −₩14.5bn | −₩14.1bn |
| Q4 2024 derived | ₩0m | – | −₩10.6bn | −₩8.9bn |
| Q3 2024 | ₩0m | – | −₩9.5bn | −₩9.4bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.
Voronoi top stories 2 weeks, by number of outlets
- 1
- 2
- 3
- 4
Latest Voronoi news Korean headlines
-
보로노이, 릴리 출신 CMO에 ‘30조 M&A 성공보수’…파격 스톡옵션의 셈법
2 more on this story · 2 outlets
- 보로노이, 릴리 출신 CMO에 ‘30조 M&A 성공보수’…파격 스톡옵션의 셈법이데일리 · Sep 14 08:01
- 보로노이, 릴리 출신 CMO에 ‘30조 M&A 성공보수’…파격 스톡옵션의 셈법이데일리증권 · Sep 14 08:01